| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 1999;100:II-24.)
© 1999 American Heart Association, Inc.
Surgery for Valvular Heart Disease |
From the Division of Thoracic and Cardiovascular Surgery and Cardiology (G.P.M.), Hannover Medical School, Hannover, Germany.
Correspondence to Wolfgang Harringer, MD, Division of Thoracic and Cardiovascular Surgery, Hannover Medical School, 30623 Hannover, Germany. E-mail harringer{at}thg.mh-hannover.de
| Abstract |
|---|
|
|
|---|
Methods and ResultsFrom July 1993 to November 1998, a
replacement of the ascending aorta with a repair of the aortic valve
was performed in 75 patients (53 men and 22 women aged 50±19 years).
Twenty-one patients (28%) had Marfan syndrome, and 11 patients (15%)
had an aortic dissection, type Stanford A (6 acute, 5 chronic). In 17
patients (23%), concomitant replacement of the aortic arch was
necessary. Clinical and echocardiographic follow-up was
performed in 6- to 12-month intervals for a cumulative study period of
137 patient-years. No operative deaths occurred. Two patients (3%)
died 5 and 20 months postoperatively. One additional patient
experienced a transient ischemic attack within the first
postoperative week. Three patients (4%) with progressive aortic
insufficiency required aortic valve replacement after 9, 11, and 14
months. All other patients had no or mild aortic insufficiency. The
repairs have now remained stable for
65 months (mean, 22±20 months).
Other valve-related complications did not occur.
ConclusionsOur results demonstrate that this type of aortic valve repair achieves excellent results in selected patients. Perfect coaptation of valve cusps during the repair with no or only trace aortic insufficiency at initial echocardiography seems to be essential for durability.
Key Words: aorta aneurysm valves regurgitation prosthesis
| Introduction |
|---|
|
|
|---|
|
Standard surgical therapy for patients reaching a critical aortic diameter or who have hemodynamically relevant aortic incompetence is the replacement of the ascending aorta and aortic valve with a valved conduit. Reported results demonstrate that this technique achieves excellent results, with low patient morbidity and mortality.5 6 7 Thromboembolic- and anticoagulant-related complications of the mechanical valve prosthesis represent a potential disadvantage in long-term patient outcome. Contrary to results of mitral valve reconstruction, aortic valve repair has led to insufficient results in the past due to high mechanical stress on the aortic valve, a relatively small cusp coaptation area, and lack of aortic root stabilization.8 Valvular incompetence resulting from distension of the aortic root, with normal valve cusps, probably represents the ideal circumstance for aortic valve repair. Various techniques have been reported in these patients for the replacement of the aneurysmatic aorta, with preservation of the valve and correction of AI.9 Since 1993, we have used the technique reported by David et al4 almost exclusively; this involves reimplantation of the aortic valve within a Dacron prosthesis. The aim of this report is to summarize our experience with this technique over a 5-year period.
| Methods |
|---|
|
|
|---|
|
In 17 patients (23%), an extension of the aneurysm into the
aortic arch was present, which required surgery. Two patients had a
re-replacement of the aortic arch, and in 4 patients, the elephant
trunk technique was used. Eight patients required additional
coronary artery revascularization, 3
patients underwent mitral valve repair due to leaflet prolapse, and 1
patient required correction of a chest-wall deformity (pectus
carinatum) as a concomitant procedure. One patient suffered from acute
dissection of the donor aorta 2 weeks after orthotopic heart
transplantation. He underwent replacement of the ascending aorta with
valve reimplantation using a nonvalved, cryopreserved, aortic
homograft. Clinical characteristics of Marfan syndrome were present
in 21 patients (28%). Our standard indications for this operation are
shown in Table 2
. In our more recent
patients, we have liberalized the criteria for valve preservation to
include patients who have aortic root diameters >4 cm with severe
valve insufficiency (n=2) and/or structurally normal bicuspid
valves (n=1).
|
Coronary angiography, aortic root angiograms, transthoracic echocardiography, and computed tomography scans or magnetic resonance images were routinely performed diagnostic procedures. The final decision to preserve the aortic valve was made intraoperatively after inspection of the valve cusps and root geometry.
Surgical Technique
Standard median sternotomy and extracorporeal circulation
techniques were used in all patients. Myocardial protection was
performed with repetitive doses of cold blood cardioplegia in an
antegrade and retrograde fashion. After aortotomy and aortic valve and
root inspection, the decision regarding valve reconstruction was made.
The excision of the coronary ostia and resection of aortic
sinuses up to a remnant of 2 to 3 mm, as well as extensive
external dissection and mobilization of the aortic root, were then
performed. Prosthesis diameters were calculated from the
diameter of the left ventricular outflow tract and the
height of the aortic cusps. Ideal valve coaptation was considered to
occur when 30% to 50% of the cusp area was involved. The mean
diameter of prostheses was 27±1.2 mm (24 mm, n=5; 26
mm, n=31; and 28 mm, n=39).
Proximal anastomosis was performed with 14 to 18 threads of 3-0 coated polyester fiber (Ethibond, Ethicon Inc) used as horizontal mattress sutures placed through the annulus underneath the valve. The aortic cuff, including the commissures, was then reimplanted into the Dacron prosthesis with three 4-0 polypropylene sutures (Prolene, Ethicon Inc) using the running technique. Utmost care was taken to achieve correct cusp geometry, sufficient height of commissural resuspension within the prosthesis, and adequate coaptation area. Anastomoses of the coronary ostia with the button technique completed the aortic root reconstruction. In cases with more extensive ascending aortic or arch replacements, a second prosthesis was used.
Follow-Up
Routine intraoperative control of aortic valve function was
determined with transesophageal
echocardiography. All patients received either
acetylsalicylic acid or warfarin for 2 months
postoperatively. Antiplatelet therapy was continued in all 8
patients who had concomitant coronary artery bypass surgery. No
patient required continuation of warfarin therapy for atrial
fibrillation. Follow-up was performed clinically with
transthoracic color Doppler
echocardiography after 3, 6, and 12 months, and at
yearly intervals thereafter. Valve morphology and systolic and
diastolic function were assessed in accordance with
published criteria.10 11 Aortic
regurgitation was assessed semiquantitatively as
follows: 0, none; I, minimal; II, mild; III, moderate; and IV, severe.
Infectious, thromboembolic, and bleeding complications were
recorded as required by the guidelines of the American
Association for Thoracic Surgery/Society of Thoracic
Surgeons.12 The cumulative follow-up period was 1645
months (137 patient-years), with a minimum of 1 month and a maximum of
65 months (mean, 22±20 months).
In a subgroup of 40 patients (28 men; mean age, 45±19 years; 15 had
Marfan syndrome) who had a follow-up of
1 year or until reoperation,
the risk for early valve regurgitation (AI>II) was
determined using the morphology of the reimplanted valve. For
this purpose, cusp coaptation area in relation to the lower edge of the
Dacron prosthesis was graded prospectively by 2 different
cardiologists using transthoracic
echocardiography before hospital discharge (Figure 2
). Aortic regurgitation
was documented at hospital discharge and at 1 year postoperatively or
immediately before reoperation.
|
Statistical Analysis
Continuous variables are expressed as mean±1SD, and
actuarial data are reported as mean probability estimates. The
statistical significance of differences in AI between preoperative and
postoperative echocardiograms was tested using paired Students
t tests. Differences in AI between groups were evaluated
with ANOVA and the Bonferroni t test. P<0.05 was
considered significant.
| Results |
|---|
|
|
|---|
|
Perioperatively, 1 patient suffered from a transient
ischemic attack (which resolved completely), and 3 patients
required rethoracotomies due to bleeding. Neither arrhythmia
nor thromboembolism was seen during follow-up. Aortic valve
incompetence was reduced significantly, from grade 2.5±0.9
preoperatively to 0.3±0.5 postoperatively (P<0.01). The
mean postoperative pressure gradient was 6±3 mm Hg, and it
remained unchanged throughout the study period. Aortic valve function
remained stable during follow-up in the majority of patients (n=68)
with either no (n=49) or minimal (n=19) aortic valve incompetence
(Figure 3
). Four patients developed
progressive AI during the first postoperative year; they are now stable
at grade II, with no further deterioration or increase in left
ventricular dimensions. Two of these patients had Marfan
syndrome. Three additional patients had reoperations 9, 11, and 14
months postoperatively due to worsening AI (grade III). At reoperation,
cusp prolapse due to inadequate technique could be identified in 2
patients; inflammatory cusp lesions were found in 1 patient with
Wegener granulomatosis, renal insufficiency, and hemodialysis. All 3
patients demonstrated less than optimal cusp coaptation with aortic
regurgitation >grade I in the early postoperative
period. At reoperation, valve replacement was performed within the
Dacron prosthesis, without difficulty, by using 23-mm
mechanical prostheses. All patients recovered promptly from the second
operation.
|
Two patients, both 76 years old, died during follow-up. One woman with ischemic heart disease died at home from sudden cardiac death 20 months postoperatively. The other patient suffered from bacterial mitral valve endocarditis 5 months after the operation. Intraoperatively, an abscess was found at the base of the anterior mitral leaflet, with a perforation between the left atrium and left ventricle; the abscess reached the aortic prosthesis in the coronary sinus. The aortic valve repair was intact, but a small perforation in the middle of the anterior cusp was found. He died of septic shock 3 days after mitral valve replacement using pericardial patch reconstruction of the left atrium and implantation of a valved conduit.
Actuarial survival and freedom from reoperation were 98.5% and 95%,
respectively, at 1 year. Both were 95% and 93% at 2 and 5 years,
respectively (Figure 4
).
|
Analysis of early repair failure (AI
II) at 1 year
postoperatively demonstrated a significant increase in aortic valve
insufficiency on echocardiography for patients with
an initial type C repair (Figure 5
). All
patients who either required reoperation or had a current AI
II were
classified as having a type C repair immediately postoperatively.
|
| Discussion |
|---|
|
|
|---|
5 years. In 4 patients, moderate
regurgitation occurred, without
hemodynamic relevance. Three other patients required
reoperation for progressive valvular insufficiency. Detailed intraoperative analysis demonstrated that resuspension of the commissures was too low in 2 patients, which led to cusp prolapse. One patient who had inflammatory disease (morbus Wegener) had thickened and shrunken leaflets, with histological evidence of inflammatory reaction in valve cusps. None of the reoperated patients had any evidence of cusp degeneration, which could result from contact with the graft or unphysiological biomechanical stress. Additionally, echocardiographic follow-up demonstrated no degenerative changes in cusps (ie, calcification, cusp perforation, or cusp thickening), which could be attributed to the above mechanisms. Modification of the surgical technique and exclusion of patients with inflammatory disease have eliminated the need for reoperation in the past 3 years. All patients demonstrated a type A or B repair in the early postoperative period. Analysis of echocardiographic morphology after valve reimplantation in our patients demonstrated the importance of proper placement of the valve inside the prosthesis.
Aggressive dissection of the aortic root and adequate height of resuspension seem to be critical technical factors. We currently dissect the aortic root as completely as possible down to the fibrous skeleton of the valve. This is sometimes difficult at the base of the right coronary sinus, where the muscle of the right ventricle has to be mobilized to seat the valve deep inside the prosthesis. Furthermore, we do not stretch the prosthesis to resuspend the commissures, which are pulled up as high as possible; we carefully assess the coaptation area of the cusps to determine if they are adequate (30% to 50% of cusp area). Thromboembolic and bleeding complications after the perioperative period were not observed. These results confirm our own early experience and the results of other published reports.15 16 17 Low perioperative morbidity and mortality as well as stable function of the reconstruction during the observation period should be noted in our series.
In addition to the aortic valve preservation technique used in our patients, an alternative surgical strategy to correct the sinotubular junction in such patients has been reported by Sarsam and Yacoub.18 Instead of resuspending the aortic valve within a prosthesis, their technique resects the aortic sinus and remodels the sinotubular junction. This minimizes the risk of cusp contact with the prosthetic wall and potentially preserves the dynamic function of the aortic root better than our technique. The reasons we continue to use David et als4 original technique are as follows: the more radical support of the diseased aortic wall, routine annular stabilization, and lesser risk for suture line leakage. Long-term results will be required for a final judgment between the 2 procedures. Thus far, we have not observed any morphological or functional degeneration of aortic valve cusps, and we have seen excellent hemodynamics. Despite these favorable initial results with valve-preserving aortic-root replacement, specific questions remain in the management of patients with Marfan syndrome.
Increasing diameters of the ascending aorta carry an elevated risk for acute aortic dissection. Elective replacement of the aortic root and ascending aorta with a valved conduit significantly improved survival in patients with Marfan syndrome.19 It is unknown to what extent the structural fibrillin-1 defect (resulting from a mutation of the fibrillin gene locus on chromosome 15) can affect the stability and durability of valve reconstruction. Recently published data confirm fibrillin fragmentation and deficiency in the aortic cusps of patients with Marfan syndrome and significant valve deterioration in patients with advanced disease.20 This contrasts with the intraoperative aspect in early disease stages and with the excellent results of valve preservation in this patient group.21 Furthermore, the risk of dissection in other aortic areas, with the need for a second or third operation, makes patient management more difficult when continuous anticoagulation is necessary. Considering these aspects, we favor this valve-preserving operation in patients with Marfan syndrome who have normal valve cusps.
A significant limitation of our technique is the short observation period of our study. The longest follow-up in our patients is 5 years; results from >9 years exist in the Toronto group.9 Yet, significant degeneration in biological valves usually occurs after 10 years. Particularly with our technique, it is still unknown whether the more rigid aortic root can lead to abnormal cusp stress and, ultimately, to early valve degeneration. Preservation of a viable valve with an ongoing cellular repair process might delay this process considerably. Therefore, continuing critical evaluation of this technique, with carefully documented patient follow-up, is necessary to allow further judgment of the risks and benefits for patients undergoing aortic root surgery. Whether it is safe to use this technique in patients with bicuspid valves and thin and pliable leaflets is yet unknown. In our opinion, selected patients most likely could benefit from this procedure if excellent initial coaptation of cusps can be achieved.
Conclusions
Our results demonstrate that valve-preserving aortic root surgery
using this innovative technique represents a true alternative
to composite graft implantation. Low perioperative
morbidity and mortality, lack of anticoagulation, and excellent
hemodynamics encourage further use of this repair.
However, a final judgment on the long-term durability of this surgical
technique will require further studies.
| References |
|---|
|
|
|---|
2.
Dapunt OE, Galla JD, Sadeghi AM, Lansman SL, Mezrow
CK, DeAsla RA, Quintana C, Wallenstein S, Ergin AM, Griepp RB. The
natural history of thoracic aortic aneurysm. J
Thorac Cardiovasc Surg. 1994;107:13231333.
3.
Kunzelman KS, Grande KJ, David TE, Cochran RP, Verrier
ED. Aortic root and valve relationships. J Thorac Cardiovasc
Surg. 1994;107:162170.
4.
David TE, Feindel CM, Bos J. Repair of the aortic
valve in patients with aortic insufficiency and aortic root
aneurysm. J Thorac Cardiovasc Surg. 1995;109:345351.
5. Mingke D, Dresler C, Stone CD, Borst HG. Composite graft replacement of the aortic root in 335 patients with aneurysm or dissection. Thorac Cardiovasc Surg.. 1998;46:1219.[Medline] [Order article via Infotrieve]
6. Gott VL, Cameron DE, Pyeritz RE, Gillinov AM, Greene PS, Stone CD, Alejo DE, McKusick VA. Composite graft repair of Marfan aneurysm of the ascending aorta: results in 150 patients. J Card Surg. 1994;9:482489.[Medline] [Order article via Infotrieve]
7. Kouchoukos NT, Wareing TH, Murphy SF, Perrillo JB. Sixteen-year experience with aortic root replacement: results of 172 operations. Ann Surg. 1991;214:308318.[Medline] [Order article via Infotrieve]
8. Duran C, Kumar N, Gometza B, al Halees Z. Indications and limitations of aortic valve reconstruction. Ann Thorac Surg. 1991;52:447453.[Abstract]
9. David TE. An anatomic and physiologic approach to acquired heart disease. Eur J Cardiothorac Surg. 1995;9:175180.[Medline] [Order article via Infotrieve]
10.
Wilkenshoff U, Kruck, I, Gast D, Schröder R.
Validity of continuous wave Doppler and color Doppler in the
assessment of aortic regurgitation. Eur
Heart J. 1994;15:12271234.
11. Nishimura R, Vonk G, Remberger J, Tajik J. Semiquantification of aortic regurgitation by different doppler echocardiographic techniques and comparison with ultrafast computed tomography. Am Heart J. 1992;124:9951001.[Medline] [Order article via Infotrieve]
12.
Edmunds LH Jr, Clark RE, Cohn LH, Grunkemeier GL,
Miller DC, Weisel RD. Guidelines for reporting morbidity and mortality
after cardiac valvular operations. Ann Thorac Surg. 1996;62:932935.
13. Kirklin JK, Smith D, Novick W, Naftel DC, Kirklin JW. Long-term function of cryopreserved aortic homografts. J Thorac Cardiovasc Surg. 1993;106:154166.[Abstract]
14. Burdon TA, Miller DC, Oyer PE, Mitchell RS, Stinson EB, Starnes VA, Shumway NE. Durability of porcine valves at 15 years in a representative North American patient population. J Thorac Cardiovasc Surg. 1992;103:238251.[Abstract]
15. Pethig K, Schäfers HJ, Borst HG. Functional results after aortic valve repair in aortic root ectasia. J Heart Valve Dis. 1996;5:247250.[Medline] [Order article via Infotrieve]
16. David TE. Aortic valve-sparing operations in patients with ascending aortic aneurysms. Curr Opin Cardiol. 1997;12:391395.[Medline] [Order article via Infotrieve]
17.
Simon P, Moritz A, Moidl R, Kupilik N, Grabenwoeger M,
Ehrlich M, Havel M. Aortic valve resuspension in ascending aortic
aneurysm repair with aortic insufficiency. Ann Thorac
Surg. 1995;60:176180.
18. Sarsam MA, Yacoub M. Remodeling of the aortic valve anulus. J Thorac Cardiovasc Surg. 1993;105:435438.[Abstract]
19. Gott VL, Pyeritz RE, Magovern GJ, Cameron DE, McKusick VA. Surgical treatment of aneurysm of the ascending aorta in the Marfan syndrome. N Engl J Med. 1986;314:10701074.[Abstract]
20.
Fleischer KJ, Nousari HC, Anahlt GJ, Stone CD,
Laschinger JC. Immunohistochemical abnormalities of fibrillin in
cardiovascular tissues in Marfans syndrome. Ann
Thorac Surg. 1997;63:10121017.
21. David TE. Aortic valve repair in patients with Marfan syndrome and ascending aorta aneurysms due to degenerative disease. J Card Surg. 1994;9:182187.[Medline] [Order article via Infotrieve]
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |